MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
StockNews.AI · 3 hours
AI Summary
MoonLake reported Week 52 Phase 3 VELA data showing 67.2% HiSCR75 and 33.1% HiSCR100 across ~396 HS patients, with meaningful QoL and pain improvements and no new safety signals. Adolescent data from VELA-TEEN also look favorable. They plan a US FDA BLA submission for HS by Sep 2026, with Priority Review possible and an Investor Day on Jun 22 to calibrate guidance.
Sentiment Rationale
Phase 3 Week 52 data show meaningful and durable efficacy with a favorable safety profile, plus a clear regulatory path (BLA end-Sep 2026 and Priority Review potential). Historical biotech moves show strong upside when a BLA submission is announced or anticipated, especially with favorable adolescent data and cleared label strategy alignment with the FDA. However, execution risk remains if the FDA requires additional data or if Priority Review isn’t granted.
Trading Thesis
Bullish: MLTX likely to react on BLA timing and potential Priority Review into late 2026, with near-term upside around the June 22 Investor Day.
Market-Moving
- Week 52 SLK efficacy metrics exceed prior HS programs, supporting label differentiation.
- BLA submission targeted for Sep 2026; PDUFA date expected by Nov 2026.
- Investor Day on Jun 22 could reset expectations for H2 milestones.
- Adolescent HS data bolster a broader label and market opportunities.
Key Facts
- VELA Week 52: SLK HiSCR75 67.2%, HiSCR100 33.1% across 396 patients.
- VELA-TEEN Week 24: HiSCR75 ~68%, HiSCR50 ~86%, HiSCR100 ~45% (n=22).
- No new safety signals through Week 52 in HS trials.
- BLA for HS planned end-Sep 2026; PDUFA date by end-Nov 2026.
- Investor Day on Jun 22, 2026 to discuss data and guidance.
Companies Mentioned
- MoonLake Immunotherapeutics (MLTX): Week 52 HS data; Investor Day June 22; HS BLA submission planned Sept 2026; potential Priority Review.
- Sanofi (SNY): Ablynx is a Sanofi company; nanobody platform context supporting MoonLake’s SLK program.
Corporate Developments
Category: Corporate Developments. This is a registrational-stage update with regulatory milestones and investor-facing events that can drive near-term valuation re-rating for MLTX.